$0.06
(5.05%)
Add to watchlist
Create an alert
Stocks and Shares ISAPliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Company Information
About this company
Key people
Bernard J. Coulie
President, Chief Executive Officer, Director
Keith Cummings
Chief Financial Officer
Minnie Kuo
Chief Operating Officer
Lily Cheung
Chief Human Resources Officer
Delphine Imbert
Chief Technical Officer
Hoyoung Huh
Non-Executive Chairman of the Board, Lead Independent Director
Suzanne Louise Bruhn
Independent Director
Darren S. Cline
Independent Director
Gayle Crowell
Independent Director
John T. Curnutte
Independent Director
Click to see more
Key facts
- Shares in issue61.45m
- EPICPLRX
- ISINUS7291391057
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$72.20m
- Employees171
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.